Form 4: Ultragenyx Director Matthew K. Fust Reports Acquisition of Stock and Options
SEC Form 4 Filing
Director Matthew K. Fust reports acquisition of Ultragenyx Pharmaceutical Inc. stock and options.
Summary
- On May 15, 2025, Matthew K. Fust, a director of Ultragenyx Pharmaceutical Inc., acquired 5,740 shares of common stock and options to purchase 10,787 shares.
- The common stock was acquired through an award of Restricted Stock Units (RSUs) under the company's 2023 Incentive Plan.
- The RSUs will vest on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.
- The option to purchase 10,787 shares has an exercise price of $34.84 and also vests on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.
- Following these transactions, Fust directly owns 25,945 shares of common stock and options for 10,787 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option acquisitions by a director. While insider buying can be seen as a positive signal, this is part of a compensation plan, so it's not necessarily indicative of strong bullish sentiment.
Positives
- The acquisition of stock and options by a director signals confidence in the company's future performance.
- The vesting schedule tied to the Annual Meeting of Stockholders aligns the director's interests with those of the shareholders.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the RSUs and options suggests a long-term commitment from the director.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's sentiment about the company's prospects.
Stakeholder Impact
- The acquisition of shares and options by a director can positively influence shareholder sentiment.
- Employees may view this as a positive sign of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 05/15/2026 | Vesting date for RSUs and stock options (or earlier if the Company's next Annual Meeting of Stockholders occurs before this date). |
| 05/15/2035 | Expiration date of the stock options. |
| 05/19/2025 | Date of signature on the Form 4 filing. |
Keywords
Ultragenyx Pharmaceutical Inc., Matthew K. Fust, Form 4, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, RARE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.